Evidence map›Paper›PMID 31951855›Full record

ArticleMolecular therapy. Nucleic acids2020

Circular RNA circFOXM1 Plays a Role in Papillary Thyroid Carcinoma by Sponging miR-1179 and Regulating HMGB1 Expression.

Mao Ye, Haitao Hou, Minghai Shen, Shu Dong, Tao Zhang

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  5. Review
  6. CircRNA-regulated glucose metabolism in ovarian cancer: an emerging landscape for therapeutic intervention.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  7. Article
  8. Review
  9. Function ofJournal of gastrointestinal oncology · 2023
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Mao YeDepartment of General Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address: yemao@zju.edu.cn.
Haitao HouDepartment of Breast and Thyroid Surgery, Tengzhou Central People's Hospital, Tengzhou 277500, China.
Minghai ShenDepartment of General Surgery, Xixi Hospital of Hangzhou, 310023 Hangzhou, China.
Shu DongJiangsu Hengrui Medicine, Jiangsu 200245, China.
Tao ZhangDepartment of General Surgery, Taizhou Traditional Chinese Medicine Hospital, Taizhou 318000, China.
Hangzhou Xixi hospital · CNJiangsu Hengrui Medicine (China) · CNSecond Affiliated Hospital of Zhejiang University · CNTengzhou Central People's Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNAs) are a class of noncoding RNAs broadly expressed in cells of various species. However, the molecular mechanisms that link circRNAs with progression of papillary thyroid carcinoma (PTC) are not well understood. In the present study, we attempted to provide a novel basis for targeted therapy for PTC from the aspect of the circRNA-microRNA (miRNA)-mRNA interaction. We investigated the expression of circRNAs in five paired PTC tissues and normal tissues by microarray analysis. The circRNA microarray assay followed by qRT-PCR was used to verify the differential expression of circFOXM1 (hsa_circ_0025033), which is located at chr12: 2966846-2983691 and derived from FOXM1. The spliced length of circFOXM1 is 3410 nt. The qRT-PCR analysis was to investigate the expression pattern of circFOXM1 in PTC tissues and cell lines. Then, the effects of circFOXM1 on tumor growth were assessed in PTC in vitro and in vivo. Furthermore, bioinformatics online programs predicted, and the luciferase reporter assay was used to validate the association of circFOXM1 and miR-1179 in PTC cells. In this study, circFOXM1 was observed to be upregulated in PTC tissues and cell lines. circFOXM1 downregulation inhibited tumor growth of PTC in vitro and in vivo. Bioinformatics analysis predicted that there is a circFOXM1/miR-1179/high-mobility group box 1 (HMGB1) axis in PTC. A dual luciferase reporter system validated the direct interaction of circFOXM1, miR-1179, and HMGB1. In summary, our study demonstrated that circFOXM1 modulates cancer progression through the miR-1179/HMGB1 pathway in PTC. Our findings indicate that circFOXM1 may serve as a promising therapeutic target for the treatment of PTC patients.

Indexed as

ceRNAcircFOXM1circRNAsPTCtarget

Identifiers

PMID31951855
PMCPMC6965511
OpenAlexW2995924232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.